Non-Small Cell Lung Cancer: key endpoint results by drug
The key endpoints of Non-Small Cell Lung Cancer trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Non-Small Cell Lung Cancer page.
PFS, median
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abemaciclib | 3.6 | 1.9 (Erlotinib) | — | n 270 | NCT02152631 Phase 3, secondary |
| Afatinib | 11.2 | 6.9 (Pemetrexed/Cisplatin) | — | 40 mg · n 230 | NCT00949650 Phase 3, primary |
| Alectinib | 10.9 | 1.4 (Premetrexed/Docetaxel) | — | n 79 | NCT02604342 Phase 3, primary |
| Alymsys (bevacizumab-maly) | 8.3 | 8.6 (Avastin) | — | wk 52 · n 315 | NCT03296163 Phase 3, secondary |
| Amivantamab | 23.7 | 16.6 (Osimertinib) | — | n 429 | NCT04487080 Phase 3, primary |
| Atezolizumab | 7 | 5.5 (Nab-Paclitaxel+Carboplatin) | — | n 456 | NCT02367781 Phase 3, primary |
| Bevacizumab | 4.8 | 3.7 | +1.1 | n 370 | NCT00257608 Phase 3, primary |
| bevacizumab-awwb | 6.6 | 7.9 (Bevacizumab) | — | n 328 | NCT01966003 Phase 3, secondary |
| Brigatinib | 24.0 | 11.1 (Crizotinib) | — | 90 mg QD/180 QD · n 137 | NCT02737501 Phase 3, primary |
| Cabozantinib | 4.6 | 4 (Docetaxel) | — | n 186 | NCT04471428 Phase 3, secondary |
| Camrelizumab | 11.3a | 8.3 (carboplatin + pemetrexed alone, PC) | — | — | NCT03134872 Phase 3, primary |
| Capmatinib | 6.1 | 4.1 (Docetaxel) | — | n 15 | NCT04427072 Phase 3, primary |
| Cemiplimab | 6.3 | 5.3 (Chemotherapy) | — | n 357 | NCT03088540 Phase 3, primary |
| Ceritinib | 16.6 | 8.1 (Chemotherapy) | — | n 189 | NCT01828099 Phase 3, primary |
| Crizotinib | 7.7 | 3 (Chemotherapy) | — | n 173 | NCT00932893 Phase 3, primary |
| Dacomitinib PF-00299804 | 14.7 | 9.2 (Gefitinib) | — | n 227 | NCT01774721 Phase 3, primary |
| Datopotamab Deruxtecan | 4.4 | 3.7 (Docetaxel) | — | 6.0 mg/kg · n 299 | NCT04656652 Phase 3, primary |
| Dostarlimab | 4.4 | 4.1 (Docetaxel) | — | n 305 | NCT04655976 Phase 2/3, secondary |
| Durvalumab | 16.8 | 5.6 | +11.2 | n 476 | NCT02125461 Phase 3, primary |
| Erlotinib | 7.6 | 6 | +1.6 | n 226 | NCT00883779 Phase 3, primary |
| Gefitinib | 5.4 | 5.4 | ±0 | n 133 | NCT01544179 Phase 3, primary |
| Gemcitabine | 5.1 | 5.5 (Chemotherapy) | — | n 396 | NCT02477826 Phase 3, primary |
| Icotinib | 4.6 | 3.4 (Gefitinib) | — | n 199 | NCT01040780 Phase 3, primary |
| Ipilimumab | 5.1 | 5.5 (Chemotherapy) | — | n 396 | NCT02477826 Phase 3, primary |
| Ixabepilone | 6.7 | 5.3 (Ixabepilone/Carboplatin) | — | n 40 | NCT00741988 Phase 2, secondary |
| Lazertinib | 20.6 | 9.7 (Gefitnib) | — | 240 mg · n 196 | NCT04248829 Phase 3, primary |
| Nab-paclitaxel | 3.1 | 2.6 | +0.5 | n 136 | NCT02027428 Phase 3, primary |
| Necitumumab | 5.7 | 5.5 (Gemcitabine + Cisplatin) | — | n 545 | NCT00981058 Phase 3, secondary |
| Niraparib | 5.5 | 5.5 | ±0 | n 200 | NCT04475939 Phase 3, primary |
| Nivolumab | 12.1 | 8.1 | +4 | n 275 | NCT03117049 Phase 3, primary |
| Oleclumab | 21.1 | 7.3 (Durvalumab Monotherapy) | — | n 60 | NCT03822351 Phase 2, secondary |
| Osimertinib | 19.5 | 22.0 (Gefitinib) | — | n 45 | NCT02856893 Phase 2, secondary |
| Pembrolizumab | 8.8 | 4.9 | +3.9 | n 410 | NCT02578680 Phase 3, primary |
| Penpulimab | 8.6a | 4.2 | +4.4 | — | NCT03866993 Phase 3, primary |
| Pralsetinib | 18.7 | 9 (SOC) | — | n 110 | NCT04222972 Phase 3, primary |
| Ramucirumab | 4.5 | 3 | +1.5 | n 628 | NCT01168973 Phase 3, secondary |
| Savolitinib | 8.2a | 4.5 (chemotherapy) | — | — | NCT05015608 Phase 3, primary |
| Selpercatinib | 24.8 | 11.2 (Pemetrexed and Platinum With Pembrolizumab) | — | n 129 | NCT04194944 Phase 3, primary |
| Sintilimab | 8.9 | 5 | +3.9 | n 266 | NCT03607539 Phase 3, primary |
| Sotorasib | 5.6 | 4.5 (Docetaxel) | — | n 171 | NCT04303780 Phase 3, primary |
| Tepotinib | 4.9 | 4.4 (Pemetrexed and Cisplatin/Carboplatin) | — | 500 mg + 250 mg · n 31 | NCT01982955 Phase 1/2, primary |
| Tislelizumab | 7.6 | 5.5 (Paclitaxel + Carboplatin) | — | n 120 | NCT03594747 Phase 3, primary |
| Toripalimab | 8.4a | 5.6 | +2.8 | — | NCT03856411 Phase 3, primary |
| Trametinib | 2.7 | 2.6 (Docetaxel) | — | 2 mg · n 86 | NCT01362296 Phase 2, primary |
| Tremelimumab | 3.9 | 5.4 (SoC Chemotherapy) | — | n 163 | NCT02453282 Phase 3, primary |
| Avelumab | 2.7b | — | — | n 42 | NCT04173507 Phase 2, secondary |
| Cetuximab | 11.9b | — | — | n 83 | NCT02438722 Phase 2/3, primary |
| Dabrafenib | 10.2b | — | — | DAB 150MG BID, TRA 2mG QD · n 48 | NCT01336634 Phase 2, secondary |
| Enfortumab Vedotin | 5.4b | — | — | n 45 | NCT04225117 Phase 2, secondary |
| Lorlatinib | 16.6b | — | — | n 30 | NCT01970865 Phase 1/2, secondary |
| Nogapendekin alfa inbakicept (Anktiva) | 5.8b | — | — | n 23 | NCT02523469 Phase 1/2, secondary |
| Olaparib | 7.1b | — | — | n 337 | NCT03976323 Phase 3, primary |
| pemetrexed | 8.4b | — | — | n 118 | NCT01017874 Phase 3, primary |
| Trastuzumab Deruxtecan | 9.5b | — | — | 6.4 mg/kg · n 50 | NCT04644237 Phase 2, secondary |
Drugs checked with no result here: 47 trial running, 38 not reported, 4 not posted.
OS, median
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abemaciclib | 7.4 | 7.8 (Erlotinib) | — | n 270 | NCT02152631 Phase 3, primary |
| Afatinib | 28.2 | 28.2 (Pemetrexed/Cisplatin) | — | 40 mg · n 230 | NCT00949650 Phase 3, secondary |
| Alectinib | 81.1 | 54.2 (Crizotinib) | — | n 152 | NCT02075840 Phase 3, secondary |
| Atezolizumab | 13.8 | 9.6 (Docetaxel) | — | n 425 | NCT02008227 Phase 3, primary |
| Bevacizumab | 9.3 | 9.2 | +0.1 | n 319 | NCT00130728 Phase 3, primary |
| Cabozantinib | 10.7 | 10.5 (Docetaxel) | — | n 186 | NCT04471428 Phase 3, primary |
| Capmatinib | 12.5 | 13.6 (Docetaxel) | — | n 15 | NCT04427072 Phase 3, secondary |
| Cemiplimab | 21.1 | 12.9 | +8.2 | n 312 | NCT03409614 Phase 3, primary |
| Ceritinib | 62.9 | 40.7 (Chemotherapy) | — | n 189 | NCT01828099 Phase 3, secondary |
| Crizotinib | 21.7 | 21.9 (Chemotherapy) | — | n 173 | NCT00932893 Phase 3, secondary |
| Dacomitinib PF-00299804 | 6.8 | 6.3 | +0.5 | n 480 | NCT01000025 Phase 3, primary |
| Datopotamab Deruxtecan | 12.9 | 11.8 (Docetaxel) | — | 6.0 mg/kg · n 299 | NCT04656652 Phase 3, primary |
| Dostarlimab | 11.9 | 11.3 (Docetaxel) | — | n 305 | NCT04655976 Phase 2/3, primary |
| Durvalumab | 11.7 | 8.7 (SoC) | — | n 62 | NCT02352948 Phase 3, primary |
| Erlotinib | 11.9 | 10.2 (Standard of Care) | — | n 245 | NCT01351415 Phase 3, primary |
| Gefitinib | 14.8 | 17.2 | −2.4 | n 133 | NCT01544179 Phase 3, secondary |
| Gemcitabine | 85.8 | — | — | n 752 | NCT00324805 Phase 3, primary |
| Icotinib | 13.3 | 13.9 (Gefitinib) | — | n 199 | NCT01040780 Phase 3, secondary |
| Ipilimumab | 13.4 | 12.4 | +0.9 | n 388 | NCT01285609 Phase 3, primary |
| Ixabepilone | 13.2 | 9.3 (Ixabepilone/Carboplatin) | — | n 40 | NCT00741988 Phase 2, secondary |
| Nab-paclitaxel | 14.2 | 13.5 (Nab-Paclitaxel + Carboplatin) | — | n 343 | NCT02367794 Phase 3, primary |
| Necitumumab | 11.5 | 9.9 (Gemcitabine + Cisplatin) | — | n 545 | NCT00981058 Phase 3, primary |
| Niraparib | 24.8 | 32.5 | −7.7 | n 200 | NCT04475939 Phase 3, secondary |
| Nivolumab | 12.2 | 9.4 (Docetaxel) | — | n 292 | NCT01673867 Phase 3, primary |
| Pembrolizumab | 15.9 | 11.3 | +4.6 | n 278 | NCT02775435 Phase 3, primary |
| Ramucirumab | 10.5 | 9.1 | +1.4 | n 628 | NCT01168973 Phase 3, primary |
| Selpercatinib | 33.0 | — | — | n 159 | NCT04194944 Phase 3, secondary |
| Sintilimab | 11.8 | 8.3 (Docetaxel) | — | n 145 | NCT03150875 Phase 3, primary |
| Tepotinib | 17.3 | 19.5 (Pemetrexed and Cisplatin/Carboplatin) | — | 500 mg + 250 mg · n 31 | NCT01982955 Phase 1/2, secondary |
| Tislelizumab | 26.1 | 19.4 (Paclitaxel + Carboplatin) | — | n 120 | NCT03594747 Phase 3, secondary |
| Trametinib | 8.1 | 9.9 (Docetaxel) | — | 2 mg · n 86 | NCT01362296 Phase 2, secondary |
| Tremelimumab | 11.9 | 16.3 (Durvalumab) | — | n 163 | NCT02453282 Phase 3, primary |
| Avelumab | 7.6b | — | — | n 42 | NCT04173507 Phase 2, secondary |
| Brigatinib | 25.9b | — | — | 90 mg · n 112 | NCT02094573 Phase 2, secondary |
| Cetuximab | 9.5b | — | — | n 233 | NCT00828841 Phase 2, primary |
| Dabrafenib | 18.2b | — | — | DAB 150MG BID, TRA 2mG QD · n 49 | NCT01336634 Phase 2, secondary |
| Lazertinib | 9.1b | — | — | 240 mg · n 11 | NCT04075396 Phase 1/2, secondary |
| Lorlatinib | 52.5b | — | — | n 27 | NCT01970865 Phase 1/2, secondary |
| Nogapendekin alfa inbakicept (Anktiva) | 12.4b | — | — | n 23 | NCT02523469 Phase 1/2, secondary |
| Olaparib | 20.7b | — | — | n 337 | NCT03976323 Phase 3, primary |
| pemetrexed | 26.9b | — | — | n 118 | NCT01017874 Phase 3, secondary |
| Pralsetinib | 39.7b | — | — | n 141 | NCT03037385 Phase 1/2, secondary |
| Sasanlimab | 14.7b | — | — | 300 mg SC · n 68 | NCT02573259 Phase 1, secondary |
| Sotorasib | 12.4b | — | — | 200 mg BIW D1D2 + 960 mg QD · n 43 | NCT05054725 Phase 2, secondary |
| Trastuzumab Deruxtecan | 17.9b | — | — | 6.4 mg/kg · n 50 | NCT04644237 Phase 2, secondary |
Drugs checked with no result here: 48 trial running, 41 not reported, 9 not posted.
ORR
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abemaciclib | 8.9% | 2.7% (Erlotinib) | — | n 270 | NCT02152631 Phase 3, secondary |
| Afatinib | 67.8% | 23% (Gemcitabine / Cisplatin) | — | 40mg · n 242 | NCT01121393 Phase 3, secondary |
| Alectinib | 82.9% | 75.5% (Crizotinib) | — | n 152 | NCT02075840 Phase 3, secondary |
| Alymsys (bevacizumab-maly) | 40.3% | 44.6% (Avastin) | — | wk 18 · n 315 | NCT03296163 Phase 3, primary |
| Atezolizumab | 11% | 10.5% (Atezolizumab IV) | — | 1875 mg · n 245 | NCT03735121 Phase 3, secondary |
| Bevacizumab | 47.6% | 42.8% (Bevacizumab (Avastin)) | — | wk 24 · n 379 | NCT02754882 Phase 3, primary |
| bevacizumab-awwb | 39% | 41.7% (Bevacizumab) | — | n 328 | NCT01966003 Phase 3, primary |
| Brigatinib | 74.5% | 62.3% (Crizotinib) | — | 90 mg QD/180 QD · n 137 | NCT02737501 Phase 3, secondary |
| Cabozantinib | 11.8% | 13.3% (Docetaxel) | — | n 186 | NCT04471428 Phase 3, secondary |
| Capmatinib | 53.3% | 0% (Docetaxel) | — | n 15 | NCT04427072 Phase 3, secondary |
| Cemiplimab | 43.6% | 22.1% | +21.5 | n 312 | NCT03409614 Phase 3, secondary |
| Ceritinib | 72.5% | 26.7% (Chemotherapy) | — | n 189 | NCT01828099 Phase 3, secondary |
| Crizotinib | 65.3% | 19.5% (Chemotherapy) | — | n 173 | NCT00932893 Phase 3, secondary |
| Dacomitinib PF-00299804 | 7.1% | 1.3% | +5.8 | n 480 | NCT01000025 Phase 3, secondary |
| Dostarlimab | 18.7% | 14.5% (Docetaxel) | — | n 305 | NCT04655976 Phase 2/3, secondary |
| Durvalumab | 60.7% | 60.6% | +0.1 | n 219 | NCT03519971 Phase 3, secondary |
| Erlotinib | 42.9% | 17.8% | +25.1 | n 226 | NCT00883779 Phase 3, secondary |
| Gefitinib | 31.6% | 34.1% | −2.5 | n 133 | NCT01544179 Phase 3, secondary |
| Gemcitabine | 36.4% | 29.7% (Chemotherapy) | — | n 396 | NCT02477826 Phase 3, secondary |
| Ipilimumab | 36.4% | 29.7% (Chemotherapy) | — | n 396 | NCT02477826 Phase 3, secondary |
| Ixabepilone | 50% | 29% (Ixabepilone/Carboplatin) | — | wk 78 · n 36 | NCT00741988 Phase 2, primary |
| Lazertinib | 76% | 76.1% (Gefitnib) | — | 240 mg · n 196 | NCT04248829 Phase 3, secondary |
| Lorlatinib | 75.8% | 57.8% (Crizotinib) | — | n 149 | NCT03052608 Phase 3, secondary |
| Nab-paclitaxel | 33% | 25% (Paclitaxel) | — | n 521 | NCT00540514 Phase 3, primary |
| Necitumumab | 31.2% | 28.8% (Gemcitabine + Cisplatin) | — | n 545 | NCT00981058 Phase 3, secondary |
| Nivolumab | 61.5% | 50.5% | +11 | n 275 | NCT03117049 Phase 3, secondary |
| Oleclumab | 35% | 23.9% (Durvalumab Monotherapy) | — | wk 16 · n 60 | NCT03822351 Phase 2, primary |
| Pembrolizumab | 47.6% | 18.9% | +28.7 | n 410 | NCT02578680 Phase 3, secondary |
| Pembrolizumab berahyaluronidase alfa | 64.3% | 18.2% (Pembrolizumab) | — | n 28 | NCT06212752 Phase 3, primary |
| Pralsetinib | 65.5% | 41.6% (SOC) | — | n 110 | NCT04222972 Phase 3, secondary |
| Ramucirumab | 22.9% | 13.6% | +9.3 | n 628 | NCT01168973 Phase 3, secondary |
| Relatlimab | 50.6% | 43% (Nivolumab + Chemotherapy) | — | wk 64 · n 158 | NCT04623775 Phase 2, primary |
| Selpercatinib | 83.7% | 65.1% (Pemetrexed and Platinum With Pembrolizumab) | — | n 129 | NCT04194944 Phase 3, secondary |
| Sintilimab | 51.9% | 29.8% | +22.1 | n 266 | NCT03607539 Phase 3, secondary |
| Tepotinib | 45.2% | 33.3% (Pemetrexed and Cisplatin/Carboplatin) | — | 500 mg + 250 mg · n 31 | NCT01982955 Phase 1/2, secondary |
| Tislelizumab | 74.2% | 47.9% (Paclitaxel + Carboplatin) | — | n 120 | NCT03594747 Phase 3, secondary |
| Tremelimumab | 34.4% | 35.6% (Durvalumab) | — | n 163 | NCT02453282 Phase 3, secondary |
| Zirabev (bevacizumab-bvzr) | 45.3% | 44.6% (Bevacizumab-EU) | — | wk 25 · n 358 | NCT02364999 Phase 3, primary |
| Apatinib | 16.7%b | — | — | 375 mg · n 12 | NCT03083041 Phase 2, primary |
| Avelumab | 2%b | — | — | n 42 | NCT04173507 Phase 2, primary |
| Binimetinib | 74.6%b | — | — | n 59 | NCT03915951 Phase 2, primary |
| Camrelizumab | 16.7%b | — | — | 375 mg · n 12 | NCT03083041 Phase 2, primary |
| Cetuximab | 67%b | — | — | n 76 | NCT02438722 Phase 2/3, secondary |
| Datopotamab Deruxtecan | 35.8%b | — | — | 6.0 mg/kg Q3W · n 137 | NCT04484142 Phase 2, primary |
| Encorafenib | 74.6%b | — | — | n 59 | NCT03915951 Phase 2, primary |
| Enfortumab Vedotin | 39%b | — | — | n 41 | NCT04225117 Phase 2, primary |
| Niraparib | 56.3%b | — | — | n 16 | NCT03308942 Phase 2, primary |
| Osimertinib | 76%b | — | — | n 25 | NCT02789345 Phase 1, secondary |
| pemetrexed | 41.5%b | — | — | n 118 | NCT01017874 Phase 3, secondary |
| Sasanlimab | 16.4%b | — | — | 300 mg SC · n 67 | NCT02573259 Phase 1, primary |
| Savolitinib | 62.1%ab | — | — | — | NCT04923945 Phase 3, primary |
| Trastuzumab Deruxtecan | 56%b | — | — | 6.4 mg/kg · n 50 | NCT04644237 Phase 2, primary |
Drugs checked with no result here: 47 trial running, 36 not reported, 8 not posted.
Duration of response, median
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Afatinib | 9.7 | 4.3 (Gemcitabine / Cisplatin) | — | 40mg · n 164 | NCT01121393 Phase 3, secondary |
| Alectinib | 42.3 | 11.1 (Crizotinib) | — | n 126 | NCT02075840 Phase 3, secondary |
| Atezolizumab | 16.3 | 6.2 (Docetaxel) | — | n 58 | NCT02008227 Phase 3, secondary |
| Bevacizumab | 9.7 | 8.4 | +1.3 | n 38 | NCT00130728 Phase 3, secondary |
| bevacizumab-awwb | 5.8 | 5.6 (Bevacizumab) | — | n 128 | NCT01966003 Phase 3, secondary |
| Brigatinib | 33.1 | 13.8 (Crizotinib) | — | 90 mg QD/180 QD · n 102 | NCT02737501 Phase 3, secondary |
| Cabozantinib | 5.5 | 4.3 (Docetaxel) | — | n 22 | NCT04471428 Phase 3, secondary |
| Capmatinib | 9.9 | 3.1 (Docetaxel) | — | n 7 | NCT04427072 Phase 3, secondary |
| Cemiplimab | 16.4 | 7.3 | +9.1 | n 136 | NCT03409614 Phase 3, secondary |
| Ceritinib | 23.9 | 11.1 (Chemotherapy) | — | n 137 | NCT01828099 Phase 3, secondary |
| Cetuximab | 4.8 | 4.8 (GCiC) | — | n 4 | NCT00870870 Phase 2, secondary |
| Crizotinib | 7.4 | 5.6 (Chemotherapy) | — | n 113 | NCT00932893 Phase 3, secondary |
| Dacomitinib PF-00299804 | 9.2 | 10.1 (Erlotinib) | — | n 52 | NCT01360554 Phase 3, secondary |
| Dostarlimab | 8.3 | 8.8 (Docetaxel) | — | n 57 | NCT04655976 Phase 2/3, secondary |
| Durvalumab | 30.7 | 18.6 | +12.1 | n 133 | NCT03519971 Phase 3, secondary |
| Erlotinib | 10.3 | 5.6 | +4.7 | n 97 | NCT00883779 Phase 3, secondary |
| Gemcitabine | 5.5 | 4.5 (Pem + Carb or Cis) | — | n 34 | NCT01160744 Phase 2, secondary |
| Ipilimumab | 25.8 | 25.2 (Durva) | — | n 194 | NCT04026412 Phase 3, secondary |
| Lazertinib | 19.4 | 8.3 (Gefitnib) | — | 240 mg · n 196 | NCT04248829 Phase 3, secondary |
| Nab-paclitaxel | 9.6 | 9.5 (Paclitaxel) | — | n 170 | NCT00540514 Phase 3, secondary |
| Nivolumab | 11 | 7 | +4 | n 275 | NCT03117049 Phase 3, secondary |
| Oleclumab | 29.9 | — | — | n 21 | NCT03822351 Phase 2, secondary |
| Pembrolizumab | 11.2 | 7.8 | +3.4 | n 195 | NCT02578680 Phase 3, secondary |
| Pralsetinib | 20.6 | 9.7 (SOC) | — | n 72 | NCT04222972 Phase 3, secondary |
| Ramucirumab | 12.9 | 5.6 (Standard of Care (Inv. Choice)) | — | n 15 | NCT03971474 Phase 2, secondary |
| Relatlimab | 8.4 | 7.1 (Nivolumab + Chemotherapy) | — | n 158 | NCT04623775 Phase 2, secondary |
| Selpercatinib | 24.2 | 11.5 (Pemetrexed and Platinum With Pembrolizumab) | — | n 108 | NCT04194944 Phase 3, secondary |
| Sintilimab | 6.0 | 5.1 | +1 | n 80 | NCT03629925 Phase 3, secondary |
| Tislelizumab | 8.4 | 4.3 (Paclitaxel + Carboplatin) | — | n 89 | NCT03594747 Phase 3, secondary |
| Trametinib | 1.6 | 2.9 (Docetaxel) | — | 2 mg · n 10 | NCT01362296 Phase 2, secondary |
| Tremelimumab | 7.4 | 6 (D + SoC) | — | n 155 | NCT03164616 Phase 3, secondary |
| Zirabev (bevacizumab-bvzr) | 8.4 | 6.6 (Bevacizumab-EU) | — | n 162 | NCT02364999 Phase 3, secondary |
| Avelumab | 7.3b | — | — | n 1 | NCT04173507 Phase 2, secondary |
| Dabrafenib | 9.8b | — | — | DAB 150MG BID, TRA 2mG QD · n 39 | NCT01336634 Phase 2, secondary |
| Enfortumab Vedotin | 7.2b | — | — | n 7 | NCT04225117 Phase 2, secondary |
| Lorlatinib | 20.9b | — | — | n 26 | NCT04362072 Phase 4, secondary |
| Niraparib | 22.8b | — | — | n 9 | NCT03308942 Phase 2, secondary |
| Nogapendekin alfa inbakicept (Anktiva) | 4.6b | — | — | n 1 | NCT02523469 Phase 1/2, secondary |
| Osimertinib | 13.4b | — | — | n 19 | NCT02789345 Phase 1, secondary |
| pemetrexed | 12.1b | — | — | n 49 | NCT01017874 Phase 3, secondary |
| Sotorasib | 12.2b | — | — | 200 mg BIW D1D2 + 960 mg QD · n 11 | NCT05054725 Phase 2, secondary |
| Trastuzumab Deruxtecan | 12.9b | — | — | 6.4 mg/kg · n 28 | NCT04644237 Phase 2, secondary |
Drugs checked with no result here: 50 trial running, 40 not reported, 11 not posted.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 143 approved or late-stage drugs with a featured trial in Non-Small Cell Lung Cancer were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.